Ovarian Cancer News
- Drug Shortages in US at 10-Year High
- J&J's Proposed Talc Settlement Would Pay $400 Million
- Asthma Tied to Increased Risk for Multiple Cancers
- Familial Cancer Risk Complex, Not Limited to Same Site
- Data Showcase Imaging Agent Utility in Lung Cancer Surgery
- Panel Backs Limited New Olaparib Use in Prostate Cancer
- DDW 2023 Bariatric Surgery Cuts Risk for Obesity-Related Cancers: Study
- Better Monitoring of Cisplatin-Induced Ototoxicity Needed
- Dismiss J&J Talc Unit New Bankruptcy, Plaintiffs Urge Judge
- Guidelines for Assessing Cancer Risk May Need Updating
- Novel ATR Inhibitor Shows Promise in Children With Tumors
- US Judge Halts Most Talc Lawsuits Against J&J, Stops Trials
- Some Benefit From Ovarian Conservation With Benign Hysterectomies
- SGO 2023 Insurers Refusing MRI for Women at High Risk for Breast Cancer
- J&J Talc Unit 2nd Bankruptcy Must Be Dismissed, Cancer Victims' Lawyers Say
- Outpatient Costs Top Drug Costs in Some Women With Breast Cancer
- UK Court Orders GSK to Pay AstraZeneca Royalties on Total Sales of Zejula
- AstraZeneca Says Drug Combo Meets Goal in Late-Stage Ovarian Cancer Trial
- SGO 2023 Mirvetuximab: Practice Changing for Some Ovarian Cancers
- SGO 2023 New Role for Olaparib in BRCA Ovarian Cancer in Neoadjuvant Setting